iBio, Inc. (NASDAQ: IBIO) reported a net loss of $33.0 million for the fiscal year ended June 30, 2026, compared with a net loss of $18.4 million in the prior year, according to a company press release.

Revenue fell to approximately $0.1 million from $0.4 million in fiscal 2025. Research and development expenses rose to $19.6 million from $8.3 million, an increase of approximately $11.3 million, driven largely by spending on consultants and outside services for the IBIO-610 and IBIO-600 programs and a $2.5 million development milestone. General and administrative expenses were roughly flat at $10.6 million. The company also recorded a $5.0 million impairment charge on an indefinite-lived intangible asset, IBIO-101.

Cash, cash equivalents, and investments in debt securities totaled approximately $88.0 million as of June 30, 2026, up from $8.6 million a year earlier. Total assets rose to $99.1 million from $23.2 million.

During the fiscal year, iBio closed a public offering in August 2025 with total potential gross proceeds of up to $100 million, assuming full cash exercise of all warrants sold, led by Balyasny Asset Management. The company also closed a $26 million private placement in January 2026 led by Frazier Life Sciences. An at-the-market sales agreement with Jefferies LLC was established for the sale of up to $100 million in common stock.

On the clinical side, iBio dosed 31 of 32 planned participants in the single ascending dose portion of a Phase 1 trial for IBIO-600, its anti-myostatin antibody, with no safety findings that precluded dose escalation. The company is preparing to advance to the multiple ascending dose portion of the trial. IBIO-610, a long-acting Activin E antibody, advanced into IND-enabling studies, and IBIO-800, a myostatin/Activin A bispecific antibody, entered IND-enabling development following candidate selection.

iBio also in-licensed AstralBio's amylin receptor antibody program and appointed Molly Carr, M.D. as Chief Medical Officer and Elizabeth Stoner, M.D. to its board of directors. The company stated its cash runway extends into fiscal year 2028.